Epizyme Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for EPIZYME INC, and when can generic versions of EPIZYME INC drugs launch?
EPIZYME INC has one approved drug.
There are twenty-two US patents protecting EPIZYME INC drugs.
There are three hundred and thirty-three patent family members on EPIZYME INC drugs in thirty-nine countries.
Drugs and US Patents for Epizyme Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Epizyme Inc | TAZVERIK | tazemetostat hydrobromide | TABLET;ORAL | 211723-001 | Jan 23, 2020 | RX | Yes | Yes | 9,549,931 | ⤷ Sign Up | ⤷ Sign Up | ||||
Epizyme Inc | TAZVERIK | tazemetostat hydrobromide | TABLET;ORAL | 211723-001 | Jan 23, 2020 | RX | Yes | Yes | 10,821,113 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Epizyme Inc | TAZVERIK | tazemetostat hydrobromide | TABLET;ORAL | 211723-001 | Jan 23, 2020 | RX | Yes | Yes | 10,369,155 | ⤷ Sign Up | ⤷ Sign Up | ||||
Epizyme Inc | TAZVERIK | tazemetostat hydrobromide | TABLET;ORAL | 211723-001 | Jan 23, 2020 | RX | Yes | Yes | 9,394,283 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Epizyme Inc | TAZVERIK | tazemetostat hydrobromide | TABLET;ORAL | 211723-001 | Jan 23, 2020 | RX | Yes | Yes | 9,175,331 | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Epizyme Inc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Singapore | 10201903356X | ⤷ Sign Up |
Lithuania | 3220916 | ⤷ Sign Up |
Japan | 2020011971 | ⤷ Sign Up |
Poland | 2836491 | ⤷ Sign Up |
Japan | 2021073241 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.